This article will be permanently flagged as inappropriate and made unaccessible to everyone. Are you certain this article is inappropriate? Excessive Violence Sexual Content Political / Social
Email Address:
Article Id: WHEBN0016370539 Reproduction Date:
Fospropofol (trade name Lusedra[3]) is an intravenous sedative-hypnotic agent. It is currently approved for use in sedation of adult patients undergoing diagnostic or therapeutic procedures such as endoscopy.
Several water-soluble derivatives and prodrugs of the widely used intravenous anesthetic agent propofol have been developed, of which fospropofol has been found to be the most suitable for clinical development thus far.[4][5] Purported advantages of this water-soluble chemical compound include less pain at the site of intravenous administration, less potential for hyperlipidemia with long-term administration, and less chance for bacteremia. Often, fospropofol is administered in conjunction with an opioid such as fentanyl.
Fospropofol is a prodrug of propofol; it is metabolized by alkaline phosphatases to an active metabolite, propofol. Theoretically, one millimole (mmol) of propofol may be generated for each mmol of fospropofol sodium administered. 1.86 mg of fospropofol sodium is the molar equivalent of 1 mg propofol.
Initial trial results on fospropofol pharmacokinetics were retracted by the investigators. As of 2011, new results were not available.[6]
Fospropofol is classified as a Schedule IV controlled substance in the United States' Controlled Substances Act.[7]
Ethanol, Hydrogen, Glucose, Antimony, Sodium
Dark matter, Rice University, Italy, Columbia University, Gran Sasso National Laboratory
Kava, Nitrogen, Alcohol, Xenon, Carbon
Kava, Alcohol, Psychology, Psychiatry, Xenon
Kava, Nitrogen, Sulfur, United States, Alcohol